Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Established safety profile

Overview Adverse events in PALOMA-2 Adverse events in PALOMA-3

(≥10%) from any cause reported in PALOMA-2 (as-treated population)2

​​​​​​​Adapted from Finn RS, et al. 2016.2

​​​​​​​Grading according to CTCAE 4.0. Data cut-off date: February 26, 2016.
*Categorised according to the MedDRA preferred terms.Febrile neutropenia was reported in 1.8% of patients in the IBRANCE + letrozole group and in no patients in the placebo + letrozole group.2 ‡In the IBRANCE + letrozole group, 30.2% of patients had Grade 1 alopecia and 2.7% had Grade 2. In the placebo + letrozole group, 14.9% of patients had Grade 1 alopecia and 0.9% had Grade 2.2

AE = adverse eventCTCAE = Common Terminology Criteria for Adverse EventsLET = letrozole​​​​​​​;  MedDRA = Medical Dictionary for Regulatory Activity; n = number of patientsPLA = placebo.


  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021.
  2. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.

Support and Services

Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.

The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.